Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: Results from a phase 1b/2 study
Số trang: 14
Loại file: pdf
Dung lượng: 915.77 KB
Lượt xem: 31
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Ibrutinib, a first-in-class inhibitor of Bruton’s tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, safety and efcacy of ibrutinib combined with companion drugs for advanced renal cell carcinoma (RCC), gastric/gastroesophageal junctional adenocarcinoma (GC), and colorectal adenocarcinoma (CRC) were evaluated.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Renal cell carcinoma Gastric adenocarcinoma Colorectal carcinoma Gastroesophageal junctional adenocarcinomaGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 141 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 115 0 0 -
12 trang 91 0 0
-
19 trang 74 0 0
-
17 trang 62 0 0
-
9 trang 39 0 0
-
11 trang 37 0 0
-
12 trang 36 0 0